KUALA LUMPUR 16 Feb - Malaysian Genomics Resource Center Berhad, a genome and biopharmaceutical company, is expected to announce significant new shareholders this week.
It is understood that the new investment in the form of equity injection is from a company not from the medical sector but engineering.
‘‘The investment will make the entry of this new entity the largest equity holder in MGRC.
"This is in line with the goal of the new entity, which intends to venture into other sectors in its expansion efforts and gain new revenue streams," said the person with the knowledge of the deal to DagangNews.com.
The company is scheduled to release its 4th Quarter result today.
Over the past few days, MGRC shares posted gains with yesterday it posted a gain of 13.56% to close at RM1.34 per share.
Malaysian Genomics Resource Center Berhad is a leading genome and biopharmaceutical company based in Southeast Asia.
The Group was established in 2004 and listed on Bursa Malaysia in 2010.
From pioneering work in genome sequencing, bioinformatics analysis, and genetic scanning services, MGRC has grown into the biopharmaceutical sector with the manufacture of cell therapies including immunotherapy for various types of cancer.
Using highly productive sequencing laboratories, advanced micro-arrangement facilities and state-of-the-art cell processing laboratories, the Group is committed to improving access to the latest accurate and personalized healthcare solutions. – DagangNews.com
Layari kami terus di DagangNews.com dan juga
Orang ramai yang ingin memberi pandangan atau suara hati, boleh menghantar tulisan ke suratpembaca@dagangnews.com dengan menyatakan:
1. Nama Pena (Jika tidak mahu guna nama sebenar).
2. Nama Sebenar seperti dalam Kad Pengenalan (Untuk rekod kami).
3. No. Telefon (untuk kami hubungi semula).
4. Menulis mengikut 5 Prinsip Rukun Negara.
5. Tidak melebihi 1,000 patah perkataan.
6. Editor berhak untuk menyunting atau menolak artikel secara profesional.
